Ysios Capital, a leading venture capital firm in the biotech sector and member of CataloniaBio & HealthTech, announced today its participation in the financing round of the Dutch company Tagworks Pharmaceuticals for a total amount of 64 million dollars (over 58 million euros). Ysios Capital has led the round together with Gilde Healthcare and has had the participation of new investors Novartis Venture Fund, New Enterprise Associates (NEA) and Lightstone Ventures, which join existing investors Meneldor and Oost NL.
The financing will support the advancement of TGW101, Tagworks’ lead click-cleavable ADC program, and the company’s proprietary Click-to-Release platform.
Thomas Harth, Principal at Ysios Capital stated: “We are proud to have assembled such a strong, international syndicate of investors around Tagworks. Click-to-Release shows tremendous potential to bring forward a new generation of biologic therapeutics with higher efficacy and improved safety that could be very meaningful for patients. We look for companies with truly differentiated approaches, and thus we are delighted to support Tagworks in its next phase of development.” He adds, "We are very proud to have gathered a syndicate of top-level investors in the US and Europe around Tagworks, which will be key to accompanying the company in its growth".
In the context of this operation, Thomas Harth (Ysios Capital), Edwin de Graaf (Gilde Healthcare), Marianne Uteng, PhD (Novartis Venture Fund), Michele Park, PhD (NEA) and Christina Isacson, PhD (Lightstone Ventures), will join the Board of Directors of Tagworks.
Photo: Thomas Harth, principal at Ysios Capital
Comments